1. Home
  2. FSLR vs INSM Comparison

FSLR vs INSM Comparison

Compare FSLR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Solar Inc.

FSLR

First Solar Inc.

HOLD

Current Price

$198.12

Market Cap

25.6B

Sector

Technology

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$144.33

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSLR
INSM
Founded
1999
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6B
30.1B
IPO Year
2006
2000

Fundamental Metrics

Financial Performance
Metric
FSLR
INSM
Price
$198.12
$144.33
Analyst Decision
Buy
Strong Buy
Analyst Count
27
24
Target Price
$241.42
$190.43
AVG Volume (30 Days)
2.1M
2.0M
Earning Date
06-01-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
18.22
N/A
EPS
14.21
N/A
Revenue
$5,219,376,000.00
N/A
Revenue This Year
$4.13
$168.46
Revenue Next Year
$15.23
$65.97
P/E Ratio
$14.10
N/A
Revenue Growth
24.09
N/A
52 Week Low
$116.56
$60.40
52 Week High
$285.99
$212.75

Technical Indicators

Market Signals
Indicator
FSLR
INSM
Relative Strength Index (RSI) 40.35 43.95
Support Level $196.80 $142.99
Resistance Level $250.73 $149.08
Average True Range (ATR) 6.16 4.08
MACD 1.13 0.37
Stochastic Oscillator 70.13 54.84

Price Performance

Historical Comparison
FSLR
INSM

About FSLR First Solar Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: